Drugs / CMV gB vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00133497 | Jun 2006 → Jun 2013 | cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00125502 | Aug 1999 → Jun 2007 | cytomegalovirus infection | Robert Pass, MD | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00299260 Comparator | Aug 2006 → Sep 2009 | cytomegalovirus infection | University College, London | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV gB vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00125502 ↗ |
| Modality | Vaccine | “a vaccine consisting of recombinant CMV envelope glycoprotein B with MF59 adjuvant” PMID 19297572 ↗ Mar 2009 |
| Route | Intramuscular | “Vaccines will be administered at 0, 1, and 6 months by intramuscular injection in the left deltoid.” NCT00125502 ↗ |